ArticleBMC cancer2026
Anesthetic-chemotherapy interplay in osteosarcoma: preliminary investigations with in vitro models.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe primary objective of this study is to evaluate whether anesthetic agents modulate the apoptotic activity and migration-inhibitory effects of chemotherapeutic agents, thereby informing the optimization of perioperative management strategies in oncologic interventions.
methodsSAOS-2 cells were treated with varying concentrations of thiopental, ketamine, and doxorubicin. Cell viability was assessed via MTT assay to determine IC₅₀ values. Thiopental exhibited greater antiproliferative activity than ketamine and was selected for further study. Its interaction with doxorubicin was analyzed using the Chou-Talalay method, yielding a combination index (CI) of 0.92608 at Fa = 0.5, indicating moderate synergism. The combination treatment also led to reduced IC₅₀ values. Cell migration was evaluated using a scratch wound healing assay. Gene expression changes related to apoptosis and metastasis were analyzed using qRT-PCR. In silico molecular docking simulations were performed to provide mechanistic insights into the observed biological effects.
resultsThiopental and doxorubicin exhibited dose-dependent cytotoxicity, with the combination showing enhanced antiproliferative activity. Co-treatment reduced IC₅₀ values and suppressed SAOS-2 cell migration more effectively than either drug alone. Gene expression analysis revealed increased pro-apoptotic markers and decreased Bcl-2 expression. Metastasis-associated genes were significantly downregulated, despite upregulation of hypoxia-responsive genes. Molecular docking analyses identified interactions of thiopental and doxorubicin with HSP70, HSP90, and CYP450, providing complementary information for the interpretation of the observed cellular responses.
conclusionThe findings suggest that thiopental may influence the cellular response to doxorubicin in osteosarcoma through treatment-associated modulation of apoptosis- and migration-related molecular responses. The observed moderate synergistic interaction and dose-reduction potential warrant further investigation in more clinically relevant experimental models.
Indexed as
Identifiers
42401870What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.